Kostas Biliouris
Stock Analyst at Oppenheimer
Total Price Targets
24
Stocks Covered
11
Sectors
Healthcare
Most Recent
Jan 28, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Kostas Biliouris
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | $21.00 | $14.45 | +45.3% | 1 | Jan 28, 2026 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $470.00 | $297.62 | +57.9% | 4 | Sep 5, 2025 |
| IONS | Ionis Pharmaceuticals, Inc. | $70.00 | $75.86 | -7.7% | 3 | Sep 3, 2025 |
| SRPT | Sarepta Therapeutics, Inc. | $50.00 | $21.60 | +131.5% | 4 | Jul 21, 2025 |
| BEAM | Beam Therapeutics Inc. | $57.00 | $31.02 | +83.7% | 2 | Nov 5, 2024 |
| FDMT | 4D Molecular Therapeutics, Inc. | $40.00 | $9.17 | +336.2% | 3 | Sep 19, 2024 |
| BMRN | BioMarin Pharmaceutical Inc. | $115.00 | $54.20 | +112.2% | 2 | Sep 17, 2024 |
| BBIO | BridgeBio Pharma, Inc. | $37.00 | $69.25 | -46.6% | 1 | Jun 5, 2024 |
| NTLA | Intellia Therapeutics, Inc. | $70.00 | $13.20 | +430.3% | 2 | May 10, 2024 |
| PRME | Prime Medicine, Inc. | $19.00 | $3.42 | +454.7% | 1 | Oct 9, 2023 |
| CRSP | CRISPR Therapeutics AG | $98.00 | $51.72 | +89.5% | 1 | Jun 17, 2022 |
Recent Activity
- Jan 28, 2026— Set$21.00price target onTRDA(Entrada Therapeutics, Inc.)
- Sep 5, 2025— Set$470.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Sep 3, 2025— Set$70.00price target onIONS(Ionis Pharmaceuticals, Inc.)
- Jul 21, 2025— Set$50.00price target onSRPT(Sarepta Therapeutics, Inc.)
- Jun 24, 2025— Set$360.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Jun 15, 2025— Set$70.00price target onSRPT(Sarepta Therapeutics, Inc.)
- Nov 5, 2024— Set$57.00price target onBEAM(Beam Therapeutics Inc.)
- Sep 19, 2024— Set$40.00price target onFDMT(4D Molecular Therapeutics, Inc.)
- Sep 17, 2024— Set$115.00price target onBMRN(BioMarin Pharmaceutical Inc.)
- Aug 27, 2024— Set$300.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Aug 2, 2024— Set$60.00price target onIONS(Ionis Pharmaceuticals, Inc.)
- Jun 27, 2024— Set$200.00price target onSRPT(Sarepta Therapeutics, Inc.)
- Jun 7, 2024— Set$170.00price target onSRPT(Sarepta Therapeutics, Inc.)
- Jun 5, 2024— Set$37.00price target onBBIO(BridgeBio Pharma, Inc.)
- May 17, 2024— Set$67.00price target onIONS(Ionis Pharmaceuticals, Inc.)
- May 10, 2024— Set$70.00price target onNTLA(Intellia Therapeutics, Inc.)
- Apr 8, 2024— Set$234.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Mar 28, 2024— Set$63.00price target onFDMT(4D Molecular Therapeutics, Inc.)
- Feb 6, 2024— Set$70.00price target onFDMT(4D Molecular Therapeutics, Inc.)
- Oct 9, 2023— Set$19.00price target onPRME(Prime Medicine, Inc.)
Frequently Asked Questions
Who is Kostas Biliouris?
Kostas Biliouris is a stock analyst at Oppenheimer covering 11 stocks primarily in Healthcare. They have issued 24 price targets since Jun 16, 2022.
What stocks does Kostas Biliouris cover?
Kostas Biliouris currently covers 11 stocks, including ALNY, SRPT, IONS, FDMT, BEAM.
What is Kostas Biliouris's latest price target?
Kostas Biliouris's most recent price target was $21.00 on TRDA (Entrada Therapeutics, Inc.), set on Jan 28, 2026.
What is Kostas Biliouris's highest price target?
Kostas Biliouris's highest issued price target is $470.00 on ALNY, set on Sep 5, 2025.
More Analysts at Oppenheimer
Coverage based on publicly published price targets. Not investment advice.